For citations:

Shestakova M.V., Ametov A.S., Antsiferov M.B., Bardymova T.P., Valeeva F.V., Galstyan G.R., Demidova T.Yu., Karpova I.A., Kiseleva T.P., Mayorov A.Yu., Mkrtumyan A.M., Nedogoda S.V., Petunina N.А., Ruyatkina L.A., Suplotova L.A., Sukhareva O.Yu., Fadeev V.V., Shamkhalova M.S. Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board. Diabetes mellitus. 2021;24(5):479-486. (In Russ.) https://doi.org/10.14341/DM12848